A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLNFGFR1)

In the phase 2, multicenter FIGHT-203 trial, patients with myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLN^FGFR1) experienced durable and high rates of complete response and complete cytogenic responses (CCyR) after receiving FGFR1-3 inhibitor pemigatinib. Data presented during the 2021 American Society of Hematology Annual Meeting show that among patients with bone marrow and/or extramedullary disease involvement, CR rates were 64.5% and 77.4%, respectively, while median durations of CR have not been reached. Among patients evaluable for cytogenic response, CCyR rates were 72.7% and 75.8%, respectively.